AdvanCell is a clinical-stage radiopharmaceutical company developing next-generation targeted alpha therapies for cancer. Through its vertically integrated platform spanning proprietary Lead-212 technology, secure isotope supply, advanced manufacturing and clinical development, the Company is unlocking the full potential of targeted alpha therapy. With integrated operations across North America and Australia, AdvanCell is advancing a pipeline of differentiated precision radiopharmaceuticals designed to improve outcomes for patients with cancer worldwide.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/16/26	$315,000,000	Series D	Abingworth Ally Bridge Group Alpha Wave Bain Capital Life Sciences Brandon Capital Partners Catalio Capital Eli Lilly Ventures Eventide Asset Management Fidelity Management & Research Company Morningside Group Piper Heartland Healthcare Capital Sanofi Ventures SV Health Investors Symbiosis T. Rowe Price Associates Tenmile Velosity Capital	undisclosed